keyword
MENU ▼
Read by QxMD icon Read
search

abatacept rheumatoid arthritis

keyword
https://www.readbyqxmd.com/read/27919316/corrigendum-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-not-previously-treated-with-disease-modifying-antirheumatic-drugs-and-after-the-failure-of-conventional-disease-modifying
#1
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo
No abstract text is available yet for this article.
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27914689/efficacy-of-biologic-therapy-across-individual-juvenile-idiopathic-arthritis-subtypes-a-systematic-review
#2
REVIEW
Rebecca Davies, Danielle Gaynor, Kimme L Hyrich, Clare E Pain
OBJECTIVE: To determine the efficacy of differing biologic therapies amongst individual juvenile idiopathic arthritis (JIA) subtypes rather than JIA overall. METHODS: A systematic literature review was conducted between January 1975 and November 2014. Studies included were randomised controlled trials, controlled trials, non-randomised prospective studies or case-control studies. Subjects were required to have a diagnosis of JIA and were ≤20 years of age at study entry...
November 1, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27914602/severe-infection-in-patients-with-rheumatoid-arthritis-taking-anakinra-rituximab-or-abatacept-a-systematic-review-of-observational-studies
#3
Vanderlea Poeys Cabral, Carlos Augusto Ferreira de Andrade, Sonia Regina Lambert Passos, Maria de Fátima Moreira Martins, Yara Hahr Marques Hökerberg
A question is raised about an increased risk of severe infection from the use of biological drugs in patients with rheumatoid arthritis. This systematic review of observational studies aimed at assessing the risk of severe infection associated with the use of anakinra, rituximab, and abatacept in patients with rheumatoid arthritis. The following databases were searched: PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta Medica Database, Scielo, and Lilacs up to July 2010. Severe infections were defined as those life-threatening ones in need of the use of parenteral antibiotics or of hospitalization...
November 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27909436/evaluation-of-anti-inflammatory-effects-of-steroids-and-arthritis-related-biotherapies-in-an-in-vitro-coculture-model-with-immune-cells-and-synoviocytes
#4
Mélissa Noack, Ndiémé Ndongo-Thiam, Pierre Miossec
BACKGROUND: During rheumatoid arthritis (RA), steroids and biotherapies are used alone and combined. Efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. METHODS: Activated-PBMC were cocultured with RA synoviocytes during 48 h...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27906048/comparative-effectiveness-of-abatacept-versus-tocilizumab-in-rheumatoid-arthritis-patients-with-prior-tnfi-exposure-in-the-us-corrona-registry
#5
Leslie R Harrold, George W Reed, Daniel H Solomon, Jeffrey R Curtis, Mei Liu, Jeffrey D Greenberg, Joel M Kremer
BACKGROUND: We compared the effectiveness of abatacept (ABA) vs tocilizumab (TCA) in tumor necrosis factor inhibitor (TNFi) experienced patients. METHODS: We identified rheumatoid arthritis (RA) patients from a large observational US cohort (1 January 2010-31 May 2014) who had discontinued at least one TNFi and initiated ABA or TCZ in moderate or high disease activity based on the Clinical Disease Activity Index (CDAI) and had no prior exposure to the comparator drug...
December 1, 2016: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/27889300/tofacitinib-versus-biologic-treatments-in-patients-with-active-rheumatoid-arthritis-who-have-had-an-inadequate-response-to-tumor-necrosis-factor-inhibitors-results-from-a-network-meta-analysis
#6
Maria-Cecilia Vieira, Samuel H Zwillich, Jeroen P Jansen, Brielan Smiechowski, Dean Spurden, Gene V Wallenstein
PURPOSE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis compared the efficacy and safety of tofacitinib with biologic disease-modifying antirheumatic drugs in patients with RA and a prior inadequate response (IR) to tumor necrosis factor inhibitors (TNFi). METHODS: A systematic literature review identified 5 randomized placebo-controlled trials that evaluated tofacitinib or biologic disease-modifying antirheumatic drugs (bDMARDs) against placebo in patient populations with RA with a prior IR to TNFi...
November 23, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27882833/evaluation-of-real-world-experience-with-tofacitinib-compared-with-adalimumab-etanercept-and-abatacept-in-ra-patients-with-1-previous-biologic-dmard-data-from-a-u-s-administrative-claims-database
#7
James Harnett, Robert Gerber, David Gruben, Andrew S Koenig, Connie Chen
BACKGROUND: Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited. OBJECTIVE: To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus the most common bDMARDs (adalimumab [ADA], etanercept [ETN], and abatacept [ABA]) following a single bDMARD in a U.S. administrative claims database. METHODS: This study was a retrospective cohort analysis of patients aged ≥ 18 years with an RA diagnosis (ICD-9-CM codes 714...
December 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27855242/biologic-or-tofacitinib-monotherapy-for-rheumatoid-arthritis-in-people-with-traditional-disease-modifying-anti-rheumatic-drug-dmard-failure-a-cochrane-systematic-review-and-network-meta-analysis-nma
#8
REVIEW
Jasvinder A Singh, Alomgir Hossain, Elizabeth Tanjong Ghogomu, Amy S Mudano, Peter Tugwell, George A Wells
BACKGROUND: We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). OBJECTIVES: To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced...
November 17, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27846756/simplified-disease-activity-index-remission-at-month-6-is-an-independent-predictor-of-functional-and-structural-remissions-at-month-12-during-abatacept-treatment-in-patients-with-rheumatoid-arthritis-a-multi-center-prospective-cohort-study-in-japan
#9
Hayato Yamazaki, Fumio Hirano, Tsutomu Takeuchi, Koichi Amano, Jun Kikuchi, Mari Kihara, Waka Yokoyama, Takahiko Sugihara, Kenji Nagasaka, Hiroyuki Hagiyama, Yoshinori Nonomura, Ryoko Sakai, Michi Tanaka, Ryuji Koike, Toshihiro Nanki, Hitoshi Kohsaka, Nobuyuki Miyasaka, Masayoshi Harigai
OBJECTIVE: To evaluate association of clinical remission at month 6 with functional and structural remissions at month 12 during abatacept treatment in patients with rheumatoid arthritis (RA). METHODS: This 12-month prospective, multicenter cohort study enrolled 168 patients with RA who started abatacept. Outcomes were assessed using composite measures, quality of life indices, and the van der Heijde-modified total Sharp score (mTSS). The logistic regression analysis was applied to identify factors associated with outcomes and their odds ratios (OR) with 95% confidence interval (95% CI)...
November 16, 2016: Modern Rheumatology
https://www.readbyqxmd.com/read/27836820/risk-of-diabetes-mellitus-associated-with-disease-modifying-antirheumatic-drugs-and-statins-in-rheumatoid-arthritis
#10
Gulsen Ozen, Sofia Pedro, Marie E Holmqvist, Michael Avery, Frederick Wolfe, Kaleb Michaud
OBJECTIVE: To investigate the rate of incident diabetes mellitus (DM) in patients with rheumatoid arthritis (RA) and the impact of disease-modifying antirheumatic drug (DMARD) and statin treatments. METHODS: We studied patients with RA and ≥1 year participation in the National Data Bank for Rheumatic Diseases without baseline DM from 2000 through 2014. DM was determined by self-report or initiating DM medication. DMARDs were categorised into four mutually exclusive groups: (1) methotrexate monotherapy (reference); (2) any abatacept with or without synthetic DMARDs (3) any other DMARDs with methotrexate; (4) all other DMARDs without methotrexate; along with separate statin, glucocorticoid and hydroxychloroquine (yes/no) variables...
November 11, 2016: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/27817127/the-conversion-rate-of-tuberculosis-screening-tests-during-biological-therapies-in-patients-with-rheumatoid-arthritis
#11
Giovanna Cuomo, Virginia D'Abrsca, Daniela Iacono, Ilenia Pantano
Screening for active tuberculosis (TB) and latent TB infection (LTBI) is mandatory to the initiation of biological therapy in patients with rheumatic diseases. To determine the prevalence of LTBI in patients with rheumatoid arthritis before treatment with biological therapy (anti-TNF, abatacept, and tocilizumab) and the rate of TB conversion during treatment in rheumatoid arthritis (RA) patients, we evaluated the file of 275 patients with RA treated with biological agents. We considered patients with negative baseline TB screening (tuberculin skin test (TST); quantiferon TB gold in tube (QFT-GIT); chest x-ray) and with rescreening for a TB assay every year...
November 5, 2016: Clinical Rheumatology
https://www.readbyqxmd.com/read/27813327/the-risk-of-hypersensitivity-associated-with-biologic-use-among-medicare-patients-with-rheumatoid-arthritis
#12
Huifeng Yun, Fenglong Xie, Randall N Beyl, Lang Chen, James D Lewis, Kenneth G Saag, Jeffrey R Curtis
BACKGROUND: Hypersensitivity reactions (HSRs) can occur with any of the available biologic drugs used to treat rheumatoid arthritis (RA). We compared drug-specific risks for HSR among RA patients enrolled in the US Medicare program. METHODS: Using Medicare data, we identified new users of infused infliximab, abatacept, rituximab, tocilizumab, golimumab, and injected biologics. After identifying HSRs using validated algorithms, for each biologic, we calculated cumulative incidence over 6 months and incidence rates (IR) within 0-1, 2-14 and 15-30 days of administration...
November 3, 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/27796445/biologic-therapies-and-bone-loss-in-rheumatoid-arthritis
#13
REVIEW
C A F Zerbini, P Clark, L Mendez-Sanchez, R M R Pereira, O D Messina, C R Uña, J D Adachi, W F Lems, C Cooper, N E Lane
INTRODUCTION: Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive inflammatory polyarthritis. One of the most deleterious effects induced by the chronic inflammation of RA is bone loss. During the last 15 years, the better knowledge of the cytokine network involved in RA allowed the development of potent inhibitors of the inflammatory process classified as biological DMARDs. These new drugs are very effective in the inhibition of inflammation, but there are only few studies regarding their role in bone protection...
October 31, 2016: Osteoporosis International
https://www.readbyqxmd.com/read/27769592/defining-the-optimal-biological-monotherapy-in-rheumatoid-arthritis-a-systematic-review-and-meta-analysis-of-randomised-trials
#14
Simon Tarp, Daniel E Furst, Anna Dossing, Mikkel Østergaard, Tove Lorenzen, Michael S Hansen, Jasvinder A Singh, Ernest H Choy, Maarten Boers, Maria E Suarez-Almazor, Lars E Kristensen, Henning Bliddal, Robin Christensen
OBJECTIVES: To summarize and compare the benefits and harms of biological agents used as monotherapy for rheumatoid arthritis (RA) in order to inform decisions for patients who are intolerant to conventional DMARD therapy. METHODS: We searched MEDLINE, EMBASE, CENTRAL, and other sources for randomised trials that compared biological monotherapy with methotrexate, placebo, or other biological monotherapies. Primary outcomes were ACR50 and the number of patients who discontinued due to adverse events...
September 14, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27757919/comparing-biologic-cost-per-treated-patient-across-indications-among-adult-us-managed-care-patients-a-retrospective-cohort-study
#15
Tao Gu, Neel Shah, Gaurav Deshpande, Derek H Tang, Debra F Eisenberg
BACKGROUND: The relative cost of biologics in the treatment of autoimmune disorders, including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a key consideration for managed care payers. OBJECTIVES: Our objective was to estimate biologic costs and treatment patterns in US managed care patients with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/or ankylosing spondylitis. METHODS: This retrospective study used administrative claims data from the HealthCore Integrated Research Database (HIRD(SM)) for adults with rheumatoid arthritis, psoriatic arthritis, psoriasis, and/or ankylosing spondylitis who received abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, or ustekinumab between 1 July 2009 and 31 January 2013...
December 2016: Drugs—Real World Outcomes
https://www.readbyqxmd.com/read/27751667/severe-infection-in-patients-with-rheumatoid-arthritis-taking-anakinra-rituximab-or-abatacept-a-systematic-review-of-observational-studies
#16
Vanderlea Poeys Cabral, Carlos Augusto Ferreira de Andrade, Sonia Regina Lambert Passos, Maria de Fátima Moreira Martins, Yara Hahr Marques Hökerberg
A question is raised about an increased risk of severe infection from the use of biological drugs in patients with rheumatoid arthritis. This systematic review of observational studies aimed at assessing the risk of severe infection associated with the use of anakinra, rituximab, and abatacept in patients with rheumatoid arthritis. The following databases were searched: PubMed, Science Direct, Scopus, Web of Knowledge, Scirus, Cochrane, Exerpta Medica Database, Scielo, and Lilacs up to July 2010. Severe infections were defined as those life-threatening ones in need of the use of parenteral antibiotics or of hospitalization...
October 1, 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27747579/incidence-of-gastrointestinal-perforations-in-patients-with-rheumatoid-arthritis-treated-with-tocilizumab-from-clinical-trial-postmarketing-and-real-world-data-sources
#17
Sharareh Monemi, Erhan Berber, Khaled Sarsour, Jianmei Wang, Kathy Lampl, Kamal Bharucha, Attila Pethoe-Schramm
INTRODUCTION: The aim of this study was to use multiple data sources to update information on gastrointestinal perforations (GIPs) during tocilizumab (TCZ) treatment in patients with rheumatoid arthritis (RA). METHODS: Reporting rates of GIP events were estimated from three distinct patient data sets: a TCZ-IV RA clinical trial all-exposure population, a global TCZ postmarketing safety database population, and a US healthcare claims database population of patients with RA, including patients who received TCZ, anti-tumor necrosis factor (aTNF) agents, or abatacept...
December 2016: Rheumatology and Therapy
https://www.readbyqxmd.com/read/27736006/body-mass-index-and-response-to-abatacept-in-rheumatoid-arthritis
#18
Anais Gardette, Sébastien Ottaviani, Jérémie Sellam, Francis Berenbaum, Frédéric Lioté, Bruno Fautrel, Elisabeth Palazzo, Alain Meyer, Jean Sibilia, Philippe Dieudé
BACKGROUND: Previous studies suggested that obesity could negatively affect the response to antitumour necrosis factor-α (TNFα) agents in rheumatoid arthritis (RA). However, data are lacking on whether obesity affects the response to abatacept (ABA). We aimed to determine whether body mass index (BMI) affects the response to ABA in RA. MATERIALS AND METHODS: In this multicenter retrospective study, we included RA patients who received ABA. BMI was calculated at the initiation of treatment...
December 2016: European Journal of Clinical Investigation
https://www.readbyqxmd.com/read/27733944/a-case-of-acute-respiratory-failure-in-a-rheumatoid-arthritis-patient-after-the-administration-of-abatacept
#19
Birsen Doğu, Nurhan Atilla, Gözde Yıldırım Çetin, Nezir Yılmaz, Hafize Öksüz
Drug-induced pulmonary disease is an important consideration in the differential diagnosis of patients with rheumatoid arthritis (RA) who present with respiratory symptoms. We report a patient with RA who developed acute respiratory failure two weeks after the administration of abatacept. The clinical findings were consistent with drug-induced acute respiratory failure, most likely acute eosinophilic pneumonia. Pulse steroid was administered at 1000 mg/kg/day in the emergency department. Chest X-ray and arterial blood gas values revealed significant improvement on the second day of hospitalization...
September 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27726046/comparative-effectiveness-of-biologics-for-the-management-of-rheumatoid-arthritis-systematic-review-and-network-meta-analysis
#20
Rafael Alfonso-Cristancho, Nigel Armstrong, Ramesh Arjunji, Rob Riemsma, Gill Worthy, Rita Ganguly, Jos Kleijnen
Our aim was to establish the comparative effectiveness of rheumatoid arthritis (RA) biologics, using a systematic review and network meta-analysis. The systematic review used randomized controlled trials (RCTs) in adults with RA who failed treatment with conventional disease-modifying agents for rheumatoid disease (cDMARDs). We compared the effectiveness of abatacept, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and rituximab to tocilizumab, a recent biologic with a different mechanism of action (anti-IL-6 receptor)...
October 10, 2016: Clinical Rheumatology
keyword
keyword
94163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"